Nicotine and Alzheimer's Disease: Dr. Ardis on Memory and Dementia

Table of Contents

1. What Dr. Ardis Says
2. Nicotine, Attention and Memory
3. Nicotinic Receptors in the Alzheimer’s Brain
4. The First Nicotine Studies in Alzheimer’s Patients
5. The 2012 Mild Cognitive Impairment Patch Trial
6. The MIND Trial
7. Galantamine: An Alzheimer’s Drug That Acts on Nicotinic Receptors
8. Smoking and Dementia in Population Studies
9. Safety Notes
10. Dr. Ardis’s Own Work
11. Key Research Papers
12. Connections
13. Featured Videos

1. What Dr. Ardis Says

Dr. Ardis set this out in a 2025 podcast appearance (Culture Apothecary) and in his book Moving Beyond the COVID-19 Lies: Restoring Health and Hope for Humanity.

He came to Alzheimer’s disease by way of Parkinson’s. Reading a report on dietary nicotine — the small amounts of nicotine found in vegetables such as tomatoes, peppers and potatoes, which he describes as able to prevent Parkinson’s — he says he went on to learn that “nicotine is known to medical science to be a curative agent and a preventative agent for Alzheimer’s,” including “the dementia related to Alzheimer’s.”

Dr. Ardis states that nicotine on its own is classed as a nootropic, which he defines as a brain stimulator: “It actually turns the brain on.” He describes the people he has in mind — people with dementia who are “having a hard time finding their words, finding their names, finding faces, finding memories” — and his answer for them: “You want to turn the brain on? Give it some nicotine. It’ll do it. It’s like caffeine, except better.”

Later in the same conversation he places Alzheimer’s in a longer list of conditions for which he states nicotine is a curative agent, “or at least an agent that would improve their symptoms mightily”: Parkinson’s, Alzheimer’s, multiple sclerosis, ulcerative colitis, all arthritis, myocarditis, autism and glioblastoma brain tumours. He states that this “has already been proven for decades,” and that the FDA and the pharmaceutical industry benefit from public fear of nicotine, because “billions of dollars’ worth every year of drugs” are prescribed for those conditions. In his view, nicotine is “an antidote to so many problems” for which patients are otherwise kept on drugs for life.

Dr. Ardis does not name a single Alzheimer’s study in this passage. The specific study is not identified here; related published work is listed below.

Back to Table of Contents

2. Nicotine, Attention and Memory

“Nootropic” is a loose, informal word for a substance that is taken to sharpen thinking. It is not a formal drug class, and caffeine is the most familiar example. Nicotine’s effects on thinking have been studied for decades, mostly in short laboratory sessions where volunteers are given nicotine or a placebo without knowing which, then tested on reaction time, attention and memory.

In 2010 researchers at the National Institute on Drug Abuse, part of the NIH, pooled 41 such double-blind, placebo-controlled studies published between 1994 and 2008 (Heishman and colleagues). All were done in healthy adults — non-smokers, or smokers who had not gone long enough without a cigarette to be in withdrawal, so that any effect could not simply be relief of craving. They found measurable improvements in six areas: fine motor skill, the accuracy and speed of “alerting” attention (staying ready for a signal), the speed of “orienting” attention (shifting to where a signal appears), the accuracy of short-term episodic memory (remembering what was just shown), and the speed of working memory (holding and using information for a few seconds). The effects were small to moderate in size. The authors concluded that these effects “likely represent true performance enhancement,” and noted that the same effects help explain why people start and keep smoking.

These are the same kinds of skills — attention, quick recall, finding the right item — that Dr. Ardis describes people with dementia losing.

Back to Table of Contents

3. Nicotinic Receptors in the Alzheimer’s Brain

Nicotine works by fitting into a family of docking sites on nerve cells called nicotinic acetylcholine receptors. Their natural partner is acetylcholine, a chemical messenger that the brain uses heavily for attention, learning and memory. When acetylcholine or nicotine binds, the receptor opens a tiny channel and the nerve cell fires. The receptors are built from subunits; the two types most studied in the brain are called α4β2 (the commonest high-affinity nicotine receptor) and α7.

Loss of acetylcholine-making nerve cells has been recognised in Alzheimer’s disease since the 1970s and 1980s, and it is the reason most Alzheimer’s drugs try to raise acetylcholine levels. The receptors were looked at next:

• 1986. Whitehouse and colleagues measured nicotinic binding sites in brain tissue taken at autopsy from people with Alzheimer’s disease and matched controls, using radioactively labelled acetylcholine and nicotine. They reported “a consistent and severe loss of nicotinic receptors” in the Alzheimer’s brains.
• 2000, Karolinska Institutet, Sweden. Guan, Nordberg and colleagues measured the individual receptor proteins in post-mortem brains. Compared with people of the same age, the Alzheimer’s brains had about 35% less α4 subunit in the hippocampus (the brain’s memory hub) and 47% less in the temporal cortex. The α7 subunit was 36% lower in the hippocampus, with no significant change in the temporal cortex. The α3 subunit was 25–29% lower; the β2 subunit did not differ.
• 2000, α7 and amyloid. Wang and colleagues reported that beta-amyloid 1–42 — the sticky protein fragment that builds up into plaques in Alzheimer’s disease — binds tightly to the α7 receptor, and that the two are found together in plaques and inside individual cortical neurons in Alzheimer’s brains. In cultured human nerve-type cells carrying extra α7 receptors, beta-amyloid killed the cells, while nicotine and another α7 activator gave protection. The authors proposed that the amyloid–α7 interaction is a key step in the disease.

These findings are the scientific basis for testing nicotine itself, and drugs aimed at nicotinic receptors, in Alzheimer’s disease. The site’s page on nicotinic acetylcholine receptors covers the receptor family in more depth.

Back to Table of Contents

4. The First Nicotine Studies in Alzheimer’s Patients

Three small studies, each with six to eight patients, opened this line of work. Each was double-blind and placebo-controlled: neither patients nor testers knew when nicotine was being given.

• Intravenous nicotine, 1988 (Newhouse and colleagues). Described by its authors as the first study to test direct nicotinic stimulation in Alzheimer’s disease. Six patients received nicotine through a drip at three doses, and a placebo. At the middle dose, patients made fewer “intrusion” errors on memory tests — recalling words that had not been on the list. The researchers also recorded dose-related increases in anxiety and low mood, and recommended further study.
• Nicotine patches, 1995 (Wilson and colleagues, Minneapolis Veterans Affairs Medical Center). Six patients with probable Alzheimer’s disease wore a placebo patch for a week, a nicotine patch for eight days, and then nothing for a week. Learning improved during the nicotine week, and the improvement persisted through the washout week. Memory, behaviour and overall cognition did not change significantly. Nicotine appeared safe, though sleep decreased.
• Four-week patch study, 1999 (White and Levin, Durham Veterans Affairs Medical Center, North Carolina). Eight otherwise healthy patients with mild to moderate Alzheimer’s disease wore a nicotine patch for 16 hours a day for four weeks (stepping from 5 mg a day to 10 mg and back to 5 mg), and a placebo patch for another four weeks, with a two-week break between. Nicotine significantly improved attention on a continuous-performance test — fewer missed targets and steadier reaction times — and the improvement lasted throughout the nicotine period. Motor and memory tests did not improve. The authors called the sustained gain in attention “encouraging,” noted that a study this small could miss subtler effects, and suggested higher doses or combinations for future trials.

Back to Table of Contents

5. The 2012 Mild Cognitive Impairment Patch Trial

Mild cognitive impairment (MCI) is the stage before dementia: memory or thinking is measurably worse than expected for a person’s age, but daily life is still largely independent. The “amnestic” type, where memory is the main problem, often goes on to Alzheimer’s disease.

In 2012 Paul Newhouse and colleagues (led from the University of Vermont, with several other centres) published the largest nicotine trial in this group up to that time, in the journal Neurology:

• Who: 74 non-smokers with amnestic MCI; 39 were assigned nicotine and 35 placebo, and 67 completed the study.
• What: a nicotine skin patch at 15 mg a day, or a matching placebo patch, for six months.
• Main findings: the primary attention test (the Conners Continuous Performance Test) showed a significant improvement with nicotine. Secondary tests showed significant nicotine-associated improvements in attention, memory and speed of mental processing, and patients and the people who knew them rated their cognitive problems as improved. The clinician’s overall rating of change (the “clinical global impression”) did not differ significantly between groups.
• Safety: the authors described safety and tolerability as excellent.

The authors concluded that the trial “provides evidence for nicotine-induced cognitive improvement in subjects with MCI,” and that larger studies would be needed to show whether the effects were clinically important. That larger study is the MIND trial, below.

Back to Table of Contents

6. The MIND Trial

The Memory Improvement through Nicotine Dosing (MIND) study, registered as NCT02720445, was designed as the follow-up to the 2012 trial. It was funded by the National Institute on Aging (NIH grant R01AG047992) and run through the Alzheimer’s Therapeutic Research Institute of the University of Southern California. Its brief summary describes daily transdermal nicotine in people with MCI, building on the finding that nicotinic receptors play a critical role in memory.

• Design: people with mild cognitive impairment were randomly assigned, half and half, to a nicotine patch or a placebo patch worn during waking hours for two years. The nicotine dose rose from 3.5 mg to 21 mg a day over the first five weeks, stayed at 21 mg to month 24, then tapered over three weeks.
• Size and dates: 380 participants were planned and 348 enrolled; the study ran from February 2017 to September 2025.
• Primary outcome: a word-list memory test (the International Shopping List Test, total immediate recall, scored 0–36) from the start of the study to month 24.

Results were first posted on the registry in September 2026. In the posted primary analysis, the estimated scores at month 24 were 16.95 in the nicotine group and 16.59 in the placebo group, with a reported p-value of 0.53 — a difference the analysis did not find statistically significant. Among the secondary measures, the posted analysis of an attention-speed task (the Identification Task) reports a p-value of 0.006. At the time of writing, no full journal report of the trial had been found indexed on PubMed; readers can follow the registry page for the complete posted results.

Back to Table of Contents

7. Galantamine: An Alzheimer’s Drug That Acts on Nicotinic Receptors

Galantamine is one of the drugs approved for mild to moderate Alzheimer’s disease. It was first isolated from snowdrop and related bulbs. Like the other drugs in its class, it slows the enzyme that breaks down acetylcholine, so more of the messenger stays available. It also does something the others mostly do not: it acts directly on nicotinic receptors.

In 2001 Maelicke and colleagues at Johannes Gutenberg University in Mainz, Germany, described this second action. Galantamine binds to nicotinic receptors at a site separate from where acetylcholine and nicotine bind, and makes the receptor more likely to open when acetylcholine or a nicotine-like compound arrives, while slowing the receptor’s tendency to switch off. They called compounds that do this “allosterically potentiating ligands” — in plain terms, a booster that turns up the receptor’s response rather than activating it on its own. They showed the effect in mouse and human neurons and in cell lines carrying several nicotinic receptor types.

In a six-month trial in 636 patients with mild to moderate Alzheimer’s disease (Raskind and colleagues, Neurology, 2000), galantamine at 24 or 32 mg a day improved scores on a standard Alzheimer’s cognitive scale by about 3.8–3.9 points compared with placebo, and improved clinicians’ overall ratings. Patients who stayed on 24 mg a day for 12 months had cognitive and daily-function scores that had not changed significantly from where they started. The commonest side effects were digestive.

Galantamine shows that turning up nicotinic signalling is already part of approved Alzheimer’s treatment, alongside the enzyme-blocking action shared by its class.

Back to Table of Contents

8. Smoking and Dementia in Population Studies

Studies that compare smokers with non-smokers measure tobacco smoke as a whole — nicotine together with thousands of combustion products — rather than nicotine on its own. Dr. Ardis himself draws this line between nicotine and smoking elsewhere in his work. The population studies on smoking and dementia have reported different results depending on how they were designed:

• Case-control studies (review, 1994). Case-control studies start with people who already have Alzheimer’s disease and look back at their habits. P. N. Lee pooled 19 of them in Neuroepidemiology and found that people who had ever smoked were less likely to have Alzheimer’s disease than people who never had (relative risk 0.64). He wrote that more data were needed to rule out confounding, and that the association was consistent with other data suggesting nicotine protects against Alzheimer’s.
• The Rotterdam Study (1998). A prospective study follows people who are free of dementia forward in time. Ott and colleagues followed 6,870 people aged 55 and over in Rotterdam, the Netherlands, for an average of 2.1 years. Current smokers had about twice the risk of developing dementia (relative risk 2.2) and Alzheimer’s disease (2.3) compared with never-smokers. The raised risk was seen in people without the APOE ε4 gene variant, and not in carriers of it.
• Meta-analysis of prospective studies (2007). Anstey and colleagues at the Australian National University pooled 19 prospective studies with 26,374 people followed for dementia for 2 to 30 years. Current smokers had a relative risk of 1.79 for Alzheimer’s disease, 1.78 for vascular dementia and 1.27 for any dementia, compared with never-smokers, and faster yearly decline on a standard memory screening test. Former smokers did not show the raised Alzheimer’s risk seen in current smokers.

The difference between the two kinds of design was discussed by the Rotterdam authors, who noted that earlier case-control studies, based on people who already had the disease, had suggested a protective effect. None of these population studies tested nicotine separated from smoke, which is the form Dr. Ardis recommends.

Back to Table of Contents

9. Safety Notes

• Keep patches away from children and pets. Nicotine is a poison at doses that are small for an adult and large for a small body. A used patch still holds a large share of its nicotine: fold it sticky-side in and dispose of it where children and animals cannot reach it. If a child or pet chews, swallows or wears a patch, call a poison control centre or a veterinarian at once.
• Who should not use nicotine without a doctor’s supervision includes people who are pregnant or breastfeeding; people with unstable heart disease, a recent heart attack or stroke, serious heart-rhythm problems or uncontrolled high blood pressure; and people with a known allergy to the patch. Nicotine can interact with other medicines.
• Side effects reported in the trials above include sleep disturbance (Wilson 1995) and, with intravenous nicotine, anxiety and low mood (Newhouse 1988). Nausea, skin irritation at the patch site and vivid dreams are common with patches generally.
• Anyone with dementia or memory problems who is considering nicotine needs a caregiver involved, since forgetting a patch is on, or applying a second one, raises the dose.

The full list of contraindications, warning signs of too much nicotine and patch-handling rules is on the Nicotine Patch Protocol page.

Back to Table of Contents

10. Dr. Ardis’s Own Work

• Moving Beyond the COVID-19 Lies — his 2024 book, whose nicotine chapter sets out the conditions he links to nicotine.
• Dr. Bryan Ardis Hub — the wing’s main page: his nicotine hypothesis and snake-venom theory, and every page in this series.
• The Dr. Ardis Show — official site

Back to Table of Contents

Key Research Papers

1. Newhouse P, Kellar K, Aisen P, et al. (2012). Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. — PubMed PMID: 22232050
2. Newhouse PA, Sunderland T, Tariot PN, et al. (1988). Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology (Berl). — PubMed PMID: 3137593
3. Wilson AL, Langley LK, Monley J, et al. (1995). Nicotine patches in Alzheimer’s disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav. — PubMed PMID: 7667377
4. White HK, Levin ED (1999). Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology (Berl). — PubMed PMID: 10326778
5. Heishman SJ, Kleykamp BA, Singleton EG (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl). — PubMed PMID: 20414766
6. Whitehouse PJ, Martino AM, Antuono PG, et al. (1986). Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res. — PubMed PMID: 3708340
7. Guan ZZ, Zhang X, Ravid R, Nordberg A (2000). Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem. — PubMed PMID: 10617125
8. Wang HY, Lee DH, D’Andrea MR, et al. (2000). beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem. — PubMed PMID: 10681545
9. Maelicke A, Samochocki M, Jostock R, et al. (2001). Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry. — PubMed PMID: 11230879
10. Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. — PubMed PMID: 10881250
11. Lee PN (1994). Smoking and Alzheimer’s disease: a review of the epidemiological evidence. Neuroepidemiology. — PubMed PMID: 8090255
12. Ott A, Slooter AJ, Hofman A, et al. (1998). Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet. — PubMed PMID: 9652667
13. Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007). Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. — PubMed PMID: 17573335

PubMed Topic Searches

1. PubMed: Transdermal nicotine and mild cognitive impairment
2. PubMed: Nicotinic receptors in Alzheimer’s disease
3. PubMed: Galantamine as a nicotinic modulator

External Authoritative Resources

• ClinicalTrials.gov: Memory Improvement Through Nicotine Dosing (MIND) Study, NCT02720445 — design and posted results of the two-year trial described in section 6.

Back to Table of Contents

Connections

• Dr. Bryan Ardis Hub — the wing’s main page: his nicotine hypothesis and snake-venom theory
• Nightshade Nicotine and Parkinson’s — the dietary-nicotine report that led him to Alzheimer’s
• Nicotinic Acetylcholine Receptors — the receptor family nicotine acts on
• The Nicotine Hypothesis — his case for nicotine separated from smoke
• Nicotine Patch Protocol — dosing, placement and the full contraindications list
• Tobacco Suppression History — his account of why therapeutic nicotine fell out of view
• Moving Beyond the COVID-19 Lies — his 2024 book
• Alzheimer’s Disease — the site’s full page on the disease
• Dementia — the wider picture of memory loss and its causes
• Choline for Cognition and Acetylcholine — the nutrient the brain makes acetylcholine from

Back to Table of Contents

Featured Videos